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Abstract 
Rationale. Pseudomonas aeruginosa (PA) is an environmental pathogen that commonly 
infects individuals with cystic fibrosis (CF) and non-CF bronchiectasis, impacting on morbidity 
and mortality. To understand the pathobiology of interactions between the bacterium and 
host adaptive immunity and to inform rational vaccine design, it is important to understand 
the adaptive immune correlates of disease. 
Objectives. We characterized T cell immunity to the PA antigen, outer membrane porin F 
(OprF), analyzing immunodominant epitopes in relation to infection status. 
Methods.  Non-CF bronchiectasis patients were stratified by frequency of PA isolation. T cell 
IFNγ immunity to OprF and its immunodominant epitopes was characterized. Patterns of 
HLA-restriction of immunodominant epitopes were defined using HLA class II transgenic 
mice. Immunity was characterized with respect to cytokine and chemokine secretion, 
antibody response and T cell activation transcripts.   
Measurements and main results.  Patients were stratified according to whether PA was 
never, sometimes (<50%) or frequently (>or=50%) isolated from sputum. Patients with 
frequent PA sputum-positive isolates were more likely to be infected by mucoid PA, and 
showed a narrow T cell epitope response and a relative reduction in Th1 polarizing 
transcription factors, but enhanced immunity with respect to antibody production, innate 
cytokines and chemokines. 
Conclusions. We have defined the immunodominant, HLA-restricted, T cell epitopes of 
OprF. Our observation that chronic infection is associated with a response of narrowed 
specificity, despite strong innate and antibody immunity, may help to explain susceptibility in 
these individuals and pave the way for better vaccine design to achieve protective immunity. 
Word count = 250 
Pseudomonas, Bronchiectasis, Adaptive Immunity, Epitopes T lymphocyte,  
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At a Glance Commentary 
Scientific Knowledge on the Subject: 
Non-CF bronchiectasis is a chronic progressive lung disease associated with impaired lung 
function, sputum production and recurrent infection. Chronic infection with the gram-negative 
bacteria Pseudomonas aeruginosa is associated with higher morbidity and mortality. It is 
unclear why, among susceptible patient groups, some individuals will develop chronic PA 
infections and others, do not. Chronic infection with PA is associated with transcriptional 
changes in bacterial gene expression, such as those associated with the development of a 
mucoid phenotype. 
 
What This Study Adds to the Field: 
In patients with non-CF bronchiectasis, we looked at immunological differences associated 
with differential susceptibility to chronic infection with PA. Patients from whom PA was 
frequently cultured from sputum tended to be infected with mucoid isolates and showed 
altered T cell immunity to an immunodominant PA antigen: T cell immunity was much more 
narrowly targeted on the PA protein, OprF despite strong innate and antibody immunity.  
These findings help to explain susceptibility to chronic infection and should prove valuable for 
vaccine design. 
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Pseudomonas aeruginosa (PA) is an environmental pathogen, able to exploit predisposing 
host conditions to cause chronic infection (1,2). Chronic respiratory PA colonization of non-
CF bronchiectasis patients impacts on morbidity and mortality (3,4). Features of host-
pathogen interplay during PA infection pose novel and important challenges. Chronic 
infection can be long term, with the pathogen locating in hypoxic masses in the airway lumen 
and an associated morphotypic shift to a biofilm state involving generation of a protective, 
alginate, exopolysaccharide coat (5,6).  This state can persist in the face of high titers of 
neutralizing antibody (6). The biofilm state is an adaptation presumed to protect the pathogen 
from host immunity (7,8), but little is known about adaptive immunity to PA during long-term 
infection.  
 
As with many other large, variable bacterial genomes, there is a paucity of data available on 
detailed mapping of functional, protective antigen targets; often there are clear data on 
serodominant targets, but ability to activate antibody can differ from the ability to elicit 
protective immunity (9). Various PA antigens have been considered in mouse, rat and non-
human primate as well as trials in human CF or non-CF vaccinees (10-16). In a phase III 
vaccine trial of non-colonized CF patients, a flagellin vaccine roughly halved the number of 
PA infections in the recipient cohort (10).  Studies have considered the lipopolysaccharide O 
antigens, flagellin and the outer membrane porins F and I (OprF and l). OprF is a major outer 
membrane protein that is conserved across clinical isolates (17-19). In comparison of aerobic 
and anaerobic PA biofilms, OprF is upregulated 39-fold during anaerobic (relative to aerobic) 
biofilm growth (6). Studies have considered the immunogenicity and protective efficacy of 
OprF (20-25), commonly focusing on OprF antibodies.  
 
Non-CF bronchiectasis offers a highly relevant clinical group in whom to map the immune 
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events predisposing to chronic PA colonization. A disease of chronic lung inflammation, 
damage and infection, it is defined by a pathological endpoint: irreversible, abnormal, 
bronchial dilatation with chronic airway inflammation, reached through diverse etiologies 
(26,27). The pathobiology suggests interplay between immunogenetic susceptibility, immune 
dysregulation, lung damage and chronic bacterial infection (27-30). Damaged epithelium 
impairs mucus removal, allowing mucus accumulation that facilitates bacterial infection, 
promoting chronic colonization associated with chronic cough and sputum production, 
recurrent chest infections and airflow obstruction. Chronic infections can encompass 
Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, and 
Pseudomonas aeruginosa as well as non-tuberculous mycobacteria, and Aspergillus 
fumigatus (26,27). Genetic associations suggest involvement of genes controlling adaptive 
immunity and innate immunity (28-30). We here analyzed adaptive immunity to PA in a 
cohort of 57 bronchiectasis patients stratified according to the frequency with which PA was 
cultured from monthly, longitudinal sputum samples.  
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Materials and Methods 
 
Patient cohort, clinical and microbiological investigations 
57 unrelated clinically stable subjects (mean age=58y±29y(2SD);28%male) with a diagnosis 
of non-CF bronchiectasis were recruited from the Royal Brompton Hospital (Table 1). 
Patients were clinically diagnosed as per the BTS bronchiectasis guidelines (28,31). Sputum 
samples were collected monthly for 6 months and sent for microscopy and culture by 
standard microbiology. Peripheral blood samples were collected. Patients were stratified into 
three groups: never (53y±31y(2SD); 29%male), less than 50% (66y±17y(2SD); 8%male), and 
more than 50% (61y±26y(2SD); 43% male) culture positive for PA in sputum samples 
collected. The study was approved under ethics code 10/H0801/53 with full, informed, patient 
consent. 
 
Production and purification of OprF protein and peptide panel 
OprF protein was produced using the recombinant vector pSUMO-OprF as described 
previously, with minor modifications (25,32). The identity and purity of OprF protein was 
confirmed by SDS-PAGE and mass spectrometry. An OprF (PA1777) peptide library 
comprising 20-mer peptides overlapping by 10 amino acids (Table 2) was synthesized (GL 
Biochem Ltd, Shanghai, China).  
 
HLA class II transgenic mice and mapping of HLA restricted T cell responses 
HLA-DR1(DRA*0101/DRB1*0101)Aβ°, HLA-DR4(DRA*0101/DRB1*0401)Aβ° and HLA-
DR15(DRA*0101/DRB1*1501)Aβ° transgenic mice described previously (33-36) aged 8-15 
weeks were used. UK Home Office regulations for animal welfare were strictly observed. 
HLA-DR1, -DR4 and –DR15 transgenic mice were footpad immunized with 25µg OprF 
emulsified in Complete Freund’s adjuvant. Popliteal draining lymph nodes were harvested at 
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day 10 and stimulated with 25µg/ml protein or individual peptides and cellular responses 
detected by murine IFNγ ELISpot (Gen-Probe Diaclone SAS, Besançon, France). 
 
Human T cell responses to OprF protein and peptide panel. Quantification of 
immunological effector proteins and OprF IgG specific ELISA 
PBMCs were stimulated with 50µg/ml protein or individual peptides and cellular responses 
detected using the ELISpotPRO Human IFNγ Kit (Mabtech, Nacka Strand, Sweden) (Table 
5B). Supernatants from PBMCs cultured with OprF protein in human IFNγ ELISpot assays 
were used to determine cytokine and chemokine levels (Table 5A) using the 30-plex Luminex 
assay (Invitrogen, Life Technologies Ltd UK) on the Bio-plex 200 system. OprF IgG antibody 
titers were determined in patient serum samples by ELISA (Table 5C). 
 
Real-time PCR analysis of patient PBMC 
PBMCS were stimulated using PMA/Ionomycin as a generic form of lymphoid activation to 
obtain a snapshot of activated transcription. RNA was prepared (Absolutely RNA microprep 
kit, Agilent Technologies, Wokingham, UK) and cDNA synthesized using SuperScript III 
reverse transcriptase (Invitrogen, Life Technologies, UK). Real time PCR reactions were 
carried out using GAPDH(PPH00150F), TBX21(PPH00396A), RORC(PPH05877A), 
Gata3(PPH02143A), S1PR1(PPH01350F)(RT2 qPCR Primer Assays, Qiagen, UK) and 
GAPDH(Hs02758991_g1), FoxP3(Hs01085834_m1) and IL10(Hs00961622_m1)(Applied 
Biosystems, USA) primers. PCR reactions were run in triplicate and Ct values obtained using 
a MX3000P real-time PCR machine (Stratagene, USA). Variance RNA amount between 
samples was controlled by normalizing to GAPDH and relative levels of gene expression 
between samples were determined using the standard curve method (Table 5D) 
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Peptide/HLA-DR binding assays 
HLA-DR heterodimers were purified and relative binding of the OprF peptide panel to the 
HLA-DR molecules HLA-DRB1*01:01, 03:01, 04:01, 07:01, 09:01, 11:01, 13:01, and 15:01 
was measured by competitive ELISA, as previously described (33-36). Data were expressed 
as relative affinity: ratio of the IC50 of the peptide to the IC50 of the reference peptide.  
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Results 
Strong T cell responses to PA protein, OprF in patients with non-CF bronchiectasis 
 
We initially compared the T cell responses to the major PA immunogen, OprF, in three 
groups of bronchiectasis patients, stratified according to whether PA was never, sometimes 
(<50%) or frequently (>=50%) cultured from monthly sputum samples collected over 6 
months (Tables 1 and 5B). Patients showed a strong IFNγ response to the protein antigen. 
Individuals that were never sputum culture positive for PA or sputum culture positive < 50% 
of the time had mean frequencies of 158 (+/- 377) and 202 (+/- 484) spot forming cells (SFC) 
/106 respectively, suggestive of robust immune memory devoted to the host PA response 
(Figure 1A). However, patients with evidence of chronic PA infection that were sputum 
culture positive for PA >=50% of the time, showed reduced responsiveness to OprF, with a 
mean response of 119 (+/- 262) SFC (Figure 1A). Patients with chronic PA infection were 
more likely to be infected by mucoid isolates (Chi-Square Test 5.42; p=0.0199, Pearson). In 
the group that were <50% sputum sample culture positive for PA, 4/12 (25%) individuals 
grew mucoid isolates and in the >=50% group, 11/14 (79%) individuals grew mucoid isolates 
(Supplementary Figure 1A). Figure 1B shows the patient ELIspot response to OprF in terms 
of infection by mucoid or non-mucoid PA isolates.  
 
Strong antibody responses to PA protein, OprF in patients with non-CF bronchiectasis 
patients with evidence of chronic PA infection. 
Next, we measured serum antibody responses to OprF in bronchiectasis patients (Table 1 & 
5C), stratified according to whether PA was never, sometimes (<50%) or frequently (>=50%) 
cultured from monthly sputum samples (Figure 1C) and according to the type of PA isolate, 
no PA, non-mucoid or mucoid PA (Figure 1D). Individuals that were sputum culture positive 
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for mucoid and non-mucoid PA made significantly stronger antibody responses to OprF than 
those that were consistently sputum culture negative for PA (mean + 2SD for mucoid PA 
(1692 ± 3059; p<0.001) and non-mucoid PA (947 ± 2355; p<0.01)) compared to culture 
negative for PA (325 ± 457). Individuals with non-CF bronchiectasis with evidence of chronic 
PA infection that were frequently culture positive for PA (>=50%) had significantly higher 
serum antibody responses to OprF (mean ± 2SD for >50% for PA (2082 ± 3131; p<0.001), 
<50% PA (414 ± 330; p<0.01) and no PA (325 ± 457)). 
 
OprF sequence contains strong HLA-DR binding epitopes 
 
Since OprF is immunogenic and protective in experimental pseudomonas [20-25] and 
seroreactive in non-CF bronchiectasis patients with chronic PA infection (37), we further 
investigated the candidacy of OprF as a CD4 T cell antigen.  A synthetic peptide panel of 
20mers overlapping by 10 amino acids was generated, covering the full coding sequence 
(Table 2) and binding affinities determined for the HLA-DR alleles, HLA-DR1, -DR3, -DR4, -
DR7, -DR9, -DR11, -DR13, and -DR1501 (Table 3).  Of the 34 peptides in the panel, over 
60% were able to bind one or more of the HLA alleles tested with moderate to high relative 
affinity, showing that OprF contains peptides that can bind across many HLA class II alleles. 
 
Narrowed OprF T cell epitope responses in non-CF bronchiectasis patients with 
chronic PA infection 
 
Patient T cell responses to OprF were epitope mapped by screening responses to an 
overlapping peptide panel spanning the full-length sequence (Tables 1 and 5B). Responses 
in non-CF bronchiectasis patients from whose sputum PA was never cultured show broad 
immune responses to multiple T cell epitopes within OprF (Figure 2A). The spread of epitope 
Page 10 of 44 AJRCCM Articles in Press. Published on 19-March-2015 as 10.1164/rccm.201411-1995OC 
 Copyright © 2015 by the American Thoracic Society 
Quigley et al.,  11
responses appeared somewhat similar in the patients who were sometimes culture positive 
(<50%) for PA. However, in the individuals with evidence of chronic PA infection, the 
response focused on a significantly smaller number of epitopes (mean ±2SD; 9±13 in the 
never-sputum PA culture-positive group, compared to 3±10 in the >50% sputum PA culture 
positive group; p<0.01).  For clarity, this relationship is displayed in Figure 2B, with patients 
stratified by mucoid morphotype of PA isolates (see also Supplementary Figure 1B). 
Representative examples of patient T cell responses to the peptide panel are shown for the 
‘never PA culture positive’ group (Figure 2C), sometimes culture-positive group (<50% of 
sputum samples) (Figure 2D) and frequently culture positive group (>=50% of sputum 
samples) (Figure 2E). The T cell response to OprF in non-CF bronchiectasis patients with 
evidence of chronic PA infection is focused on fewer epitopes within the antigen. Since it was 
theoretically possible that breadth of epitope recognition was simply a correlate of overall 
magnitude of response to the protein, we checked to see if such a correlation could be 
determined, but found none (Supplementary Figure 2). The notion that breadth of epitope 
recognition is not a simple correlate of magnitude of response to the whole antigen is further 
supported by analysis of those specific epitopes most commonly recognized by T cells from 
the patients in each group (Figure 2F); while some epitopes were recognized by some 
donors from each of the groups, others were more commonly recognized by individuals from 
one group or another. 
 
CD4 T cell epitope responses to OprF peptide panel in HLA class II transgenic mice 
Because of the difficulties inherent in any attempt to impute patterns of peptide-HLA class II 
restriction in human populations where most individuals will be heterozygotes across the HLA 
region and, furthermore, each antigen presenting cell (APC) will express multiple, different 
HLA class II heterodimers, we compared patterns of CD4 OprF epitope recognition from 
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patients to the pattern of responses in HLA transgenic mice (Figure 3). For this, we used a 
panel of mice that carry a knockout for endogenous mouse H2-Aβ and utilize human HLA 
class II heterodimers, HLA-DR1, DR4 and DR15.  As can be seen in Figure 3, screening of 
OprF epitopes in the context of individual HLA-DR molecules allows for unequivocal 
attribution of peptides presented in this context: the response of HLA-DR1 transgenics 
focuses on p4, of DR4 transgenics on p6, 14 and 15 and of DR15 on p11. While the 
complexities of human T cell repertoire selection and immunogenetics make it challenging to 
juxtapose findings in HLA transgenics and in humans, comparison of the response patterns 
offers some insights as to peptide-HLA complexes involved in the PA response.  
 
We next looked at to what extent p11, the sole immunodominant epitope presented to CD4 T 
cells by HLA-DR15 in transgenic mice, features in the T cell response of patients who carry 
one or two HLA-DR15 alleles. It is one of the more common epitopes in HLA-DR15+ patients, 
and 7/14 (50%) individuals in the group from which PA was never cultured respond to p11. 
However, for individuals with evidence of PA infection in the sputum, this epitope was 
recognized in only 1/9 (11%) of HLA-DR15+ patients (Fisher Exact Probability Test: two 
tailed, p=0.0858). The number / percentage of individuals carrying the HLA-DR1501 allele did 
not significantly differ between groups [n=14/31 (44%) for never PA culture positive vs n=6/14 
(43%) for >or=50% culture positive]. Thus, the altered disease state to chronic infection may 
be associated not just with a quantitative diminution in T cell response but in a qualitative 
shift in the recognition of immunodominant epitopes. 
 
Enhanced cytokine and chemokine responses in non-CF bronchiectasis patients with 
evidence of chronic PA infection 
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Despite a substantially reduced antigen and peptide specific IFNγ response to PA OprF, the 
patients with evidence of chronic PA infection showed an enhanced response with respect to 
a number of innate cytokines and chemokines when compared to responses in patients from 
whom PA was never isolated (Table 5A and Figure 4). This increased response 
encompassed significantly raised levels of IL-12, IL-6, MIP-1α (CCL3) and MIP-1β, 
collectively suggesting increased chemotaxis for neutrophils, monocytes and NK cells. IL-8 
was also increased, although this difference did not reach significance. A small, but 
significant increase in secreted IL-4 may indicate a Th2-skewed program in these individuals. 
 
Lymphocyte transcriptional changes in non-CF bronchiectasis patients with evidence 
of chronic PA infection 
 
PBMC responses to OprF suggested an immune profile in chronically infected individuals 
whereby antigen specific IFNγ T cell effector responses are narrowed in epitope specificity, 
but the innate/inflammatory and antibody response is enhanced. We therefore investigated 
whether there was evidence for any intrinsic difference between patient groups in terms of 
transcripts associated with T cell adaptive immunity programs (Table 5D & Figure 5). We 
looked at the hallmark transcription factors of Th1, Th17 and Th2 cells, that is, TBX21, RORC 
and Gata3. We also looked at S1P receptor 1 (S1pr1) transcription, a molecule implicated in 
T cell trafficking between tissues and lymph nodes. Transcripts for TBX21 were significantly 
reduced in PBMC samples from patients that were frequently (>=50%) sputum culture 
positive for PA compared to those that were never sputum culture positive for PA (Figure 5A). 
This is suggestive of a relative reduction in Th1 programmes in non-CF bronchiectasis 
patients with evidence of chronic PA infection. No change was seen with respect to 
transcription of Gata3, the Th2 transcription factor (Figure 5D) and RORC the Th17 
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transcription factor is reduced, but this did not achieve significance (Figure 5C). We found no 
evidence that these changes may have been mediated through a systemic bias to a more 
regulated phenotype: transcription of FoxP3 and IL10 was also reduced, though this did not 
reach statistical significance (Figure 5 E,F). Transcription of S1pr1 was significantly reduced 
in PBMC of the chronic PA carriers relative to PBMC from individuals who were never culture 
positive for PA (Figure 5B). 
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Discussion 
 
OprF has received attention as an immunogen that confers protection in murine challenge 
studies and trialled for immunogenicity as a PA vaccine in humans (11-13,15,16, 22-25).  It is 
an abundantly expressed outer membrane protein of PA, initially characterized with respect 
to anchoring to the peptidoglycan layer (38) and with a structural role in adhesion to 
eukaryotic cells (39).  It is upregulated during biofilm formation under anaerobic conditions 
and the airway mucus of some CF patients contains cleaved OprF protein. OprF antibody 
titer is regarded a potential biomarker of biofilm infection (6).  OprF binds IFNγ, leading to 
stimulation of the quorum sensing network (40). Oprf deletion mutants define a role of OprF 
in virulence, partly through modulation of quorum-sensing (41). 
In light of this evidence for OprF immunogenicity and hyper-expression during biofilm 
formation, it might be predicted that patients undergoing such infection would show enhanced 
OprF adaptive immunity:  it has previously been shown by others and confirmed by us that 
chronic infection is associated with raised antibody titers (6,37). Studies in a mouse infection 
model allowing comparison of PA that was either alginate wild-type, hyper-expressing or null, 
showed that alginate over-expression was associated with poor bacterial clearance and 
exacerbated lung pathology, yet with heightened pro-inflammatory cytokines – that is, raised 
IFNγ and IL-12 but lower IL-10 in lung homogenates (7). However, in other studies, mucoid or 
biofilm phenotypes are associated with reduced innate immunity (8,42). The present study 
shows that patients with chronic PA infection have reduced T cell immunity to OprF, although 
with enhanced innate immunity with respect to several innate cytokines and chemokines. 
OprF has intrinsic ability to stimulate release of diverse innate cytokines from dendritic cells 
(43); while this clearly would not have contributed to the differences in epitope focus we 
observed in peptide-specific CD4 responses, it may be that in chronically PA infected 
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patients showing up-regulated OprF, this up-regulation may stimulate increased systemic IL-
12 and TNFα. From our study we cannot be certain whether the altered T cell response 
pattern we observed is cause or effect of a heightened susceptibility to PA infection. It is 
likely that polymorphisms in pathways underpinning both innate and adaptive immunity to PA 
contribute to susceptibility (27-30). Certainly the enhanced innate inflammatory response will 
contribute to the progressive lung damage, deterioration in lung function and associated 
increased morbidity and mortality seen in non-CF bronchiectasis patients with chronic PA 
infection (4) 
A key finding here was the narrowed repertoire of T cell OprF epitopes during chronic PA 
infection. This raises the question whether functional clearance of PA by adaptive immunity 
benefits most from a highly focused or a more diffuse response. The issue of epitope focus 
versus breadth has been considered most extensively in relation to viral infections, including 
HIV, CMV and HCV. SIV and HIV studies have argued variously that either a very broad or a 
very focused repertoire response can be correlated with better control of infection and 
improved outcome (44-46). In the case of PA, curated sequences for OprF are largely 
conserved and indeed, the epitopes we have characterized in the present study are highly 
conserved across diverse Pseudomonas family members, including Pseudomonas 
alcaligenes, indica, citronellolis and stutzeri. Thus, in principle, a T cell response targeted at 
any epitope should be able to support a protective response. This suggests that the 
correlation of multiple epitopes with effective host immunity may lie not in the breadth of 
epitope responses per se but in the cumulative frequency of responding cells. 
 
This study showed a strong correlation between chronic PA infection and mucoid isolates, 
making it difficult to establish whether the driving correlate of altered adaptive immunity in 
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chronic infection is the altered morphotype/transcriptome itself, or some other parameter of 
chronic infection (for example, the altered inflammatory environment). Changes in the 
bacterial transcriptome with shift to a mucoid morphotype are considerable, with likely 
impacts on innate recognition, phagocytosis and uptake, and accessibility to proteolytic 
enzymes for antigen processing. It is noteworthy, however, that the change in T cell epitope 
recognition in chronically infected patients is not just a matter of ‘missing responses’. For 
example, a response to p22 is seen most commonly in the chronic infection group (data not 
shown). 
 
At the same time as analyzing antigen specific changes at the level of epitope recognition, 
we analyzed systemic changes in adaptive immunity programs at the level of T cell 
transcription. Individuals from whom PA was never isolated in sputum show heightened 
PBMC transcription of the Th1-controlling transcription factor, Tbet and the S1P1 receptor, 
implicated in both CNS and lung lymphocyte trafficking (47). A relative reduction in Tbet 
transcription in chronic infection may indicate an intrinsic defect in (or, at least, progam bias 
away from) Th1 polarization. Related observations have focused on the corollary of this: a 
switch to Th2 immunity (48).  Tbet was first defined as a hallmark transcription factor for 
differentiation of Th1 cells, and since then, has often been taken as a biomarker of Th1 
immunity (49); in Tbet knockout mice the key phenotype relates to Th1 defects (50,51). 
However, alterations in Tbet transcription may encompass programmatic changes in other 
cell types - CD8 cells, NK cells, ILCs, dendritic cells and B cells (52-56). The lipid second 
messenger, S1P and its receptor, S1PR1, control lymphoid organ egress, trafficking and T 
cell subset determination (57). Our finding that patients with chronic PA infection have an 
intrinsic reduction in S1PR1 lymphocyte expression may help explain their abnormal 
immunity to infection, suggesting the potential for therapy via modulation of this this pathway. 
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With relatively large numbers of multiple sclerosis patients receiving Fingolimod (FTY720, 
S1P analog) as a new therapeutic of choice, there is a case for increased clinical vigilance for 
possible breakdown of lung surveillance of respiratory infections (58). The reduction in RORC 
transcription in chronic PA patients did not achieve significance, but the findings appear 
compatible with a trend to reduced systemic Th17 immunity. The importance of Th17 
immunity is highlighted by a study from Chan and colleagues, showing enhanced antigen 
specific Th17 responses in DLNs of explanted lungs of CF patients, suggesting that this 
subset may be important for lung immunity (59).  Patients chronically sputum PA culture 
positive show a trend to reduced systemic FoxP3 and IL10 transcription, compatible with the 
notion that defects in immune regulation may contribute to an inflammatory environment that 
facilitates PA lung infection (60). 
 
It has become apparent that chronic immune stimulation, commonly by tumor antigens or 
viral antigens, can lead to an 'exhausted' T cell phenotype, characterized by raised 
expression of PD-1 (61). Since the example of chronic PA infection encompasses protracted 
immune exposure to enhanced antigen expression and yet results in lowered rather than 
heightened T cell immunity, it is interesting to speculate that this may constitute a bacterial-
driven example of exhaustion. Alternatively, other lung co-infections could be contributing to 
an altered immune environment in the lung. The lung is a complex immunological 
environment, with interplay between innate and adaptive receptors and signals from diverse 
microbial species (27). This encompasses not just co-infections identified in sputum by 
standard microbiology, but also the microbiota species which are far from immunologically 
silent. A fully integrated analysis of the interplay between immune and microbial repertoires is 
both necessary and timely. We have previously reported observations on the 
immunogenetics of susceptibility to idiopathic bronchiectasis in terms of HLA-C and DR 
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(28,29). Determining within this patient group the genetic factors driving susceptibility to 
chronic PA infection is an important goal, but a much larger cohort would need to be enrolled 
into a study dedicated to specifically address this question. 
 
While a number of PA vaccines have been trialed including those utilizing OprF, OprI and 
Flagellin (10-16, 20-25), studies such as this one raise an additional possibility of exploiting 
the potency and flexibility of incorporating a large number of stimulatory T and B cell epitopes 
into epitope string vaccines. In other contexts, such as P. falciparum vaccination, these can 
be successfully administered in a ‘prime-boost’ regime through incorporation into an 
adenoviral vector followed by DNA boost (62). The appeal of the approach to a patient group 
such as this would be the ability to tailor a polyvalent construct to cover several different 
pathogens, including PA. 
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Table 1. Study subjects 
Underlying 
cause of non-
CF 
bronchiectas 
Patient 
ID 
Age 
(years) 
Sex 
(M/F) 
HLA-Cw HLA-DR 
Percent of 
sputum samples 
culture positive 
for 
Pseudomonas 
aeruginosa 
(0%, <50%, >50%)
 
Other pathogens isolated in  
sputum  
PCD B01 57 F 6 7 11 15 0% H. influenza, S. pneumonia 
CVID B03 66 F 7 8 1 17 0% 
 
H. influenza, S. pneumoniae, M. 
catarrhalis 
Post Infective B10 71 F 10 16 4 7 0% URT flora, S. aureus 
Idiopathic B09 62 F 7 7 15 17 0% - 
Post Infective B18 76 M 6 10 13 14 0% - 
Idiopathic B19 40 M 1 4 4 12 0% - 
Idiopathic B25 75 M 4 7 1 1 0% - 
Idiopathic B26 77 F 12 14 4 10 0% URT flora 
Idiopathic B28 64 F 5 7 17 4 0% URT flora 
Post Infective B29 31 F 4 15 14 15 0% - 
Idiopathic B33 42 M 5 7 4 13 0% URT flora 
PCD B35 40 F 7 7 1 15 0% S. aureus 
PCD B36 59 F 9 7 11 13 0% URT flora, S. maltophillia 
PCD B38 22 F 6 12 17 11 0% 
 
H. influenza, S. pneumoniae, M. 
catarrhalis, S. aureus 
Post Infective B39 51 F 4 5 1 14 0% URT flora, S. aureus 
Youngs B45 59 M 1 4 4 15 0% H. influenza 
Post Infective B46 29 F 8 10 4 7 0% S. pneumonia 
ABPA B27 56 F 10 6 17 13 0% URT flora, Aspergillus fumigatus 
ABPA B55 60 M 10 10 7 15 0% URT flora 
CVID B56 41 F 1 5 1 11 0% URT flora, H. influenza 
Post Infective B54 59 F 6 10 7 13 0% URT flora, H. influenza 
ABPA B63 27 F 7 7 4 11 0% URT flora. S. aureus 
Idiopathic B77 64 M 7 12 15 17 0% URT flora, M. catarrhalis 
PCD B79 33 F 2 12 4 13 0% URT flora, M. catarrhalis, H. influenza 
Idiopathic B83 55 M 5 7 7 15 0% URT flora 
Post Infective B73 60 M 7 7 4 15 0% URT flora, S. pneumoniae, Coliform 
Youngs B64 62 F 5 7 15 17 0% URT flora, Candida albicans 
PCD B72 29 F 7 16 11 15 0% URT flora, S. aureus, S pneumonia 
Idiopathic B74 61 F 7 7 4 15 0% URT flora, S. aureus 
Post Infective B75 64 F 7 6 1 15 0% URT flora, H. influenza 
Post Infective B62 53 F 7 7 15 15 0% H. influenza 
 
 
ABPA B12 67 M 4 7 1 14 
 
<50% 
3/7 non-mucoid S. aureus 
 
 
Post Infective B17 72 F 1 7 1 15 
<50% 
 1/6 non-mucoid URT flora 
 
 
Idiopathic B31 72 F 7 14 1 17 
<50% 
2/6 mucoid;  URT flora, P. vulgaris 
 
 
Idiopathic B43 61 F 1 12 1 12 
<50% 
3/8 mucoid URT flora 
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Post Infective B48 81 F 10 15 4 9 
<50% 
1/6 non-mucoid URT flora 
 
 
Idiopathic B50 64 F 7 5 7 15 
<50% 
1/7 non-mucoid URT flora, M. catarrhalis, S. maltophillia 
 
 
Idiopathic B52 52 F 7 7 1 7 
<50% 
1/9 non-mucoid 
 
URT flora, Coliform, S. maltophillia,   
S. aureus 
 
 
Idiopathic 
 
 
B76 
 
 
67 
 
 
F 
 
 
7 
 
 
8 
 
 
1 
 
 
17 
 
 
<50% 
1/9 non-mucoid 
 
 
URT flora, β- Haemo Streptococcus 
group C 
 
 
Post Infective B78 72 F 1 1 8 14 
<50% 
2/7 mucoid URT flora, Candida albicans 
 
 
Post Infective B81 63 F 7 9 17 7 
<50% 
2/7 non-mucoid URT flora, H. influenza, S. aureus 
 
 
PCD B68 53 F 4 12 15 4 
<50% 
3/8 non-mucoid URT flora 
 
 
Post Infective B71 68 F 2 14 1 4 
<50% 
1/7 mucoid S. aureus 
 
 
Idiopathic B02 78 F 2 7 4 17 
>=50% 
4/8 mucoid M. catarrhalis 
 
 
Post Infective B13 70 M 6 12 11 14 
>=50% 
7/7 mucoid - 
 
 
Post Infective B14 65 M 14 16 7 9 
>=50% 
7/7 mucoid - 
 
 
ABPA B16 64 M 7 10 1 7 
>=50% 
5/7 mucoid S. aureus, H. influenza 
 
 
Post Infective B21 62 F 9 7 7 15 
>=50% 
7/7 mucoid - 
 
 
PCD B23 30 M 7 7 4 15 
>=50% 
1/1 mucoid - 
 
 
ABPA B40 64 M 4 7 1 13 
>=50% 
5/7 mucoid Candida albicans 
 
 
Post Infective B47 72 F 7 8 4 14 
>=50% 
4/4 non-mucoid - 
 
 
Idiopathic B57 76 F 4 12 4 15 
>=50% 
4/7 mucoid - 
 
 
ABPA B82 60 M 7 12 13 17 
>=50% 
6/7 mucoid - 
 
 
Post Infective B67 66 F 17 4 1 7 
>=50% 
4/7 non-mucoid URT flora, Aspergillus fumigatus 
 
 
ABPA B70 55 F 5 7 4 15 
>=50% 
7/7 mucoid - 
 
 
Idiopathic B61 57 F 7 12 1 15 
>=50% 
5/7 mucoid URT flora 
 
 
PCD B85 39 F 7 10 4 15 
>=50% 
6/6 non-mucoid 
 
 
aSputum samples were collected monthly for six months and analysed by microscopy and culture using 
standard microbiology techniques. Patients were divided into three groups defined by the % of sputum cultures 
collected that were positive for P. aeruginosa (0%,<50%, and >=50%). The column also shows the number of 
sputum samples positive for mucoid isolates over the total number of sputum samples collected and analyzed. 
Where no mucoid P. aeruginosa was isolated the number of sputum samples positive for non-mucoid isolates is 
given over the total number of sputum samples collected. 
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Table 2. OprF peptide panel 
 
An OprF peptide library comprising 20-mer peptides overlapping by 10 amino acids was 
synthesized from the sequence of OprF, PA1777 (GL Biochem Ltd, Shanghai, China).  
 
Peptide  
number 
Peptide name Peptide sequence 
1 PA1777 [1-20] MKLKNTLGVVIGSLVAASAM 
2 PA1777 [11-30] IGSLVAASAMNAFAQGQNSV 
3 PA1777 [21-40] NAFAQGQNSVEIEAFGKRYF 
4 PA1777 [31-50] EIEAFGKRYFTDSVRNMKNA 
5 PA1777 [41-60] TDSVRNMKNADLYGGSIGYF 
6 PA1777 [51-70] DLYGGSIGYFLTDDVELALS 
7 PA1777 [61-80] LTDDVELALSYGEYHDVRGT 
8 PA1777 [71-90] YGEYHDVRGTYETGNKKVHG 
9 PA1777 [81-100] YETGNKKVHGNLTSLDAIYH 
10 PA1777 [91-110] NLTSLDAIYHFGTPGVGLRP 
11 PA1777 [101-120] FGTPGVGLRPYVSAGLAHQN 
12 PA1777 [111-130] YVSAGLAHQNITNINSDSQG 
13 PA1777 [121-140] ITNINSDSQGRQQMTMANIG 
14 PA1777 [131-150] RQQMTMANIGAGLKYYFTEN 
15 PA1777 [141-160] AGLKYYFTENFFAKASLDGQ 
16 PA1777 [151-170] FFAKASLDGQYGLEKRDNGH 
17 PA1777 [161-180] YGLEKRDNGHQGEWMAGLGV 
18 PA1777 [171-190] QGEWMAGLGVGFNFGGSKAA 
19 PA1777 [181-200] GFNFGGSKAAPAPEPVADVC 
20 PA1777 [191-210] PAPEPVADVCSDSDNDGVCD 
21 PA1777 [201-220] SDSDNDGVCDNVDKCPDTPA 
22 PA1777 [211-230] NVDKCPDTPANVTVDANGCP 
23 PA1777 [221-240] NVTVDANGCPAVAEVVRVQL 
24 PA1777 [231-250] AVAEVVRVQLDVKFDFDKSK 
25 PA1777 [241-260] DVKFDFDKSKVKENSYADIK 
26 PA1777 [251-270] VKENSYADIKNLADFMKQYP 
27 PA1777 [261-280] NLADFMKQYPSTSTTVEGHT 
28 PA1777 [271-290] STSTTVEGHTDSVGTDAYNQ 
29 PA1777 [281-300] DSVGTDAYNQKLSERRANAV 
30 PA1777 [291-310] KLSERRANAVRDVLVNEYGV 
31 PA1777 [301-320] RDVLVNEYGVEGGRVNAVGY 
32 PA1777 [311-330] EGGRVNAVGYGESRPVADNA 
33 PA1777 [321-340] GESRPVADNATAEGRAINRR 
34 PA1777 [331-350] TAEGRAINRRVEAEVEAEAK 
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Table 3. OprF peptide relative binding affinity to HLA-DR molecules 
OprF 
peptide DR1 DR3 DR4 DR7 DR9 DR11 DR13 DR1501 
p1 1 >1 060 3 2 10 50 >309 4 
p2 2 >1 060 3 4 3 11 >309 3 
p3 13 >1 060 350 9 23 756 2 94 
p4 1,134 224 10 964 420 75 3 173 
p5 15 >1 060 249 1,420 122 1,500 >309 3 
p6 36 21 11 10 52 354 >309 49 
p7 1,793 >1 060 >2 968 534 37 >4 297 >309 81 
p8 1,120 >1 060 >2 968 >5 056 >1 642 537 >309 >1 119 
p9 15 533 2,000 1,412 >1 642 1,333 >309 1,771 
p10 18 447 753 91 42 129 >309 8 
p11 112 >1 060 67 67 39 548 200 0.5 
p12 8,571 >1 060 >2 968 >5 056 >1 642 >4 297 >309 >1 119 
p13 11,429 26 1,333 355 345 1,500 >309 417 
p14 11 23 283 49 13 707 2 67 
p15 8 >1 060 5 >5 056 13 22 >309 20 
p16 2,673 >1 060 >2 968 9,412 574 149 >309 1,458 
p17 4,286 >1 060 >2 968 1,765 548 4,167 >309 >1 119 
p18 66 >1 060 460 127 57 420 >309 123 
p19 212 >1 060 4,333 241 177 8,333 >309 1,250 
p20 28,571 >1 060 6,000 11,765 >1 642 >4 297 >309 >1 119 
p21 20,000 >1 060 >2 968 >5 056 >1 642 6,667 >309 >1 119 
p22 3,714 683 >2 968 7,059 >1 642 >4 297 >309 >1 119 
p23 94 >1 060 >2 968 >5 056 >1 642 >4 297 >309 >1 119 
p24 >11 262 >1 060 >2 968 >5 056 >1 642 >4 297 >309 >1 119 
p25 2,857 13 1,467 1,412 237 2,083 >309 833 
p26 822 >1 060 258 1,065 1,200 335 >309 70 
p27 71 >1 060 103 80 85 866 169 4 
p28 >11 262 >1 060 >2 968 >5 056 >1 642 >4 297 >309 >1 119 
p29 1,225 >1 060 >2 968 1,412 600 342 >309 1,042 
p30 949 >1 060 467 142 63 1,667 >309 38 
p31 90 >1 060 161 290 64 130 >309 33 
p32 35 >1 060 >2 968 183 31 391 >309 15 
p33 14,286 >1 060 2,667 >5 056 3,600 2,917 >309 >1 119 
p34 >11 262 >1 060 >2 968 >5 056 >1 642 7,500 >309 >1 119 
  
*Results are expressed as a relative binding ratio obtained by dividing the IC50 of each 
peptide by that of a reference peptide that binds strongly to the HLA molecule tested. Lower 
numbers correspond to a higher binding affinity. Numbers in red (ratio of 20 or less) = high 
affinity binding; numbers in green (ratio 20-100) = moderate binding affinity. Each peptide - 
MHC combination was evaluated in 2 independent experiments. 
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Table 4. Cytokine and chemokine responses in non-CF bronchiectasis. 
Immunological protein 
Never culture 
positive 
(pg/ml) 1 
Culture  
positive >50% 
(pg/ml) 2 
P value 
 
Cytokines 
GM-CSF 136 ± 25 240 ± 50 
 
 
G-CSF 348 ± 77 779 ± 258 
 
 
TNFα 517 ± 96 1027 ± 319 
 
 
IFNα 3.9 ± 2 10.7 ± 6 
 
 
IL-1β 1671 ± 175 2315 ± 276 
 
 
IL-2 0.2 ± 0.05 0.2± 0.1 
 
 
IL-4 1.2 ± 0.4 3.6 ± 0.9 ** 
 
IL-5 0.5 ± 0.1 0.8 ± 0.3 
 
 
IL-6 5339.1 ± 1508 12772 ± 3401 * 
 
IL-7 15.1 ± 2 21.6 ± 5.8 
 
 
IL-8 35230 ± 17683 95584 ± 34319 
 
 
IL-10 88.3 ± 21 159 ± 68 
 
 
IL-12 12.4 ± 2 24.9 ± 5 * 
 
IL-13 1.1 ± 0.3 2.2 ± 0.7 
 
 
IL-15 52.8 ± 10 60.6 ± 28 
 
 
IL-17 0.1 ± 0.05 0.3 ± 0.2 
 
 
IL-1RA 0 0 
 
 
IL-2R 53.8 ± 11 83.5 ± 25 
 
Chemokines MIP-1α 7338 ± 2465 18963 ± 4145 * 
 
MIP-1β 1215 ± 230 4038 ± 1040 ** 
 
RANTES 161 ± 36 202 ± 46 
 
 
EOTAXIN 0.05 ± 0.02 0.05 ± 0.02 
 
 
IP-10 1.9 ± 0.7 2.7 ± 2 
 
 
MCP1 0 0 
 
 
MIG 2.5 ± 1 2.3 ± 2 
 
Growth 
Factors 
VEGF 72.1 ± 13 78.3 ± 32 
 
 
EGF 1.3 ± 0.3 0.6 ± 0.3 
 
 
HGF 3.1 ± 1 3.0 ± 2 
 
 
FGF 6.6 ± 1 7.8 ± 2 
 
__________________________________________________________________________________ 
1Never (0%) (n=13 for IL-6, Mip1α and IL-8; n=24 for MIP-1β and IL-12) or 2frequently (>50%) 
(n=12 for IL-6, Mip1α and IL-8; n=8 for MIP-1β and IL-12) culture positive for PA. Data is 
presented ±SEM. Statistical significance was determined using the Mann-Whitney U test       
(*, p<0.05; **, p<0.01). 
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Table 5. Subjects used in T cell functional analysis 
 
A. Luminex  
Group Classification Luminex protein 
Age 
(±2SD) Sex 
n 
number 
Never culture positive for PA 
IL-6/IL-8/MIP-1α 52 ±33 11F/2M 13 
 
All other 
proteins 
 
51 ±30 
 
18F/6M 
 
24 
 
>50 % cultures positive for PA 
 
 
IL-6/IL-8/MIP-1α 64 ±21 7F/5M 12 
 
All other 
proteins 
 
55 ±28 
 
4M/4F 
 
8 
 
 
B. ELISpot  
Group Classification Age (±2SD) Sex 
n 
number 
Never sputum culture positive for PA 53 ±31 22F/9M 31 
<50 % of sputum cultures positive for PA 66 ±17 11F/1M 12 
>50 % of sputum cultures positive for PA 61 ±26 8F/6M 14 
 
C. ELISA  
Group Classification Age(±2SD) Sex 
n 
number 
Never sputum culture positive for PA 54±31 33F/12M 45 
<50 % of sputum cultures positive for PA 64 ±23 14F/2M 16 
>50 % of sputum cultures positive for PA 61 ±22 10F/10M 20 
 
 
D. Real-time PCR  
Group Classification Age (±2SD) Sex 
n 
number 
Never culture positive for PA 47 ±32 6F/1M 7 
>50 % of sputum cultures positive for PA 58 ±26 2F/2M 4 
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Legends 
 
Figure1 
T cell and serum antibody responses to PA protein, OprF in patients with non-CF 
bronchiectasis. 
(A) The magnitude of the T cell response to OprF and control anti-CD3 in the 3 
bronchiectasis groups classified according to the PA infection status were determined (Never 
(0%) n=31; sometimes (<50%) n=12 and frequent (>=50%) n=14 culture positive for PA). In 
the group that were <50% sputum sample culture positive for PA, 4/12 (25%) individuals 
grew mucoid isolates and in the >=50% group, 11/14 (79%) individuals grew mucoid isolates. 
(Chi-Square Test 5.42; p=0.0199, Pearson). (B) The magnitude of the T cell response to 
OprF and control anti-CD3 dependant of PA isolate cultured (Never (0%) n=31, non-mucoid 
n=11 or mucoid n=15). (C) The IgG OprF specific antibody titers in the 3 bronchiectasis 
groups classified according to the PA infection status were determined (Never (0%) n=45; 
sometimes (<50%) n=16 and frequent (>=50%) n=21). (D) The IgG OprF specific antibody 
titers dependant on PA isolate cultured (Never (0%) n=45, non-mucoid n=17 or mucoid 
n=19). Data is presented ±SEM. Statistical significance was determined using the Kruskal 
wallis test followed by a post Dunn’s test. (*, p<0.05; **, p<0.01, ***p<0.001). 
 
Figure 2. T cell epitope responses to OprF peptide panel in non-CF bronchiectasis 
patients with evidence of chronic PA infection. 
Epitope mapping of patient T cell responses to OprF were determined by screening 
responses to an overlapping peptide panel of OprF in (A) for PA infection status: Never (0%) 
n=31; sometimes (<50%) n=12 and frequent (>=50%) n=14 culture positive or (B) PA isolate:  
never PA positive n=31, non-mucoid n=11 or mucoid n=15. Representative examples of 
patient T cell responses to the peptide panel are shown for the never (0%) (C), sometimes 
(<50%) (D) and frequently (>=50%)(E) culture positive. (F) The overlapping relationships of 
epitopes identified in bronchiectasis patients with PA isolates classified as never PA culture 
positive (n=31), non-mucoid (n=11) and mucoid (n=15) positive cultures visualized as a Venn 
diagram. Data is presented ±SEM. Statistical significance was determined using the Kruskal 
Wallis  Test followed by a post Dunn’s test. (*, p<0.05, **, p<0.01) 
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Figure 3. CD4 T cell epitope responses to OprF peptide panel in HLA class II 
transgenic mice 
Draining lymph nodes from transgenic mice for DRB1*0101, n=15 (A), DRB1*0401, n=9 (B) 
and DRB1*1501, n=10 (C) were harvested 10 days post immunization with OprF protein in 
CFA. Recall peptide responses were determined using the overlapping peptide panel for 
OprF. Responses were considered positive if the response was >2SD above the mean of the 
negative control.  
 
Figure 4. Cytokine and chemokine responses to OprF protein in non-CF bronchiectasis 
with evidence of chronic PA infection. 
Pro-inflammatory cytokine concentrations for (A) IL-6, (B) Mip1α, (C) Mip1β, (D) IL-12 and 
(E) IL-8 were determined from the supernatant of PBMCs stimulated with OprF. 
Concentrations were measured using the 30-plex Luminex assay in bronchiectasis patients 
classified as never (0%) (n=13 for IL-6, Mip1α and IL-8; n=24 for MIP-1β and IL-12) or 
frequently (>=50%) (n=12 for IL-6, Mip1α and IL-8; n=8 for MIP-1β and IL-12) culture positive 
for PA. Data is presented ±SEM. Statistical significance was determined using the Mann-
Whitney U test  (*, p<0.05; **, p<0.01). 
 
Figure 5. Lymphocyte transcriptional changes in non-CF bronchiectasis patients with 
evidence of chronic PA infection. 
The expression of (A) TBX21, (B) S1pr1, (C) RORc, (D) Gata3, (E) FoxP3 and (F) IL10 
were determined by qRTPCR. PBMCS were stimulated with PMA/Ionomycin from which RNA 
was isolated and converted to cDNA. Patients with broncheiectasis were classified as never 
(0%) (n=7) or frequently (>50%) (n=4) culture positive for PA. Data is presented ±SEM. 
Statistical significance was determined using the Mann-Whitney U test  
(*, p<0.05). 
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Supplementary Figure 1. T cell responses to the PA protein, OprF and number of T cell epitope 
responses to OprF peptide panel in patients with non-CF bronchiectasis.  
 
(A) The magnitude of the T cell response to OprF and control anti-CD3; and (B) the number of T cell 
epitopes identified in the 3 bronchiectasis groups classified according to the PA infection status. Never 
(0%,  circle) n=31; sometimes (<50%, square) n=12 and frequent (>=50%, triangle) n=14 culture positive 
for PA). Blue indicates no PA; Black indicates non-mucoid PA; and green indicates mucoid PA. Data is 
presented ±SEM. Statistical significance was determined using the Kruskal wallis  test followed by a post 
Dunn’s test. (**, p<0.01). In the group that was <50% sputum sample culture positive for PA, 4/12 (25%) 
individuals grew mucoid isolates and in the >=50% group, 11/14 (79%) individuals grew mucoid isolates. 
(Chi-Square Test 5.42; p=0.0199, Pearson).  
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Supplementary Figure 2 
Supplementary Figure 2. Magnitude of OprF T cell response does not correlate with number of 
OprF epitopes recognized across this non-CF bronchiectasis cohort. 
  
There is no correlation between the magnitude of the T cell response to OprF and the number of 
responding peptides determined for each of the 3 non-CF bronchiectasis cohorts classified according to 
the PA infection status (Never (0%) n=31; sometimes (<50%) n=12 and frequent (>50%) n=14 PA 
culture positive). Statistical significance was determined using the Spearman’s rank correlation. Never 
(blue circle; r=0.01), sometimes <50% (orange square; r=0.38), and frequently >50% (green triangle; 
r=0.38) sputum culture positive for PA.  
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